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Heart failure (HF) is a clinical syndrome that is increasingly
affecting elderly patients. Before 2000, the mean age at
diagnosis of HF was 63 years, but has more recently
increased to 80 years (1). Similarly, the incidence of new-
onset HF is much higher in elderly patients compared
with younger patients, and registry data show that the
proportion of hospitalizations with a diagnosis of HF and
the prevalence of HF in the general population is much
higher in older patients (2).
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Consequently, most studies focused on HF in the elderly
patients, traditionally deﬁned as >65 years of age, but more
recently deﬁned as >85 years of age (3). Few studies
described clinical characteristics and outcome in younger
patients. However, they generally used a threshold of 65
years of age, and hardly any study focused on younger
patients with HF, those <40 to 50 years of age. Interest-
ingly, but not unexpectedly given the low number of young
patients with HF, the majority of these studies are case
reports. Therefore, the paper by Wong et al. (4) in the
present issue in the Journal appears to be of particular
interest.
The investigators performed a post-hoc analysis of the
CHARM (Candesartan in Heart Failure Assessment of
Reduction in Mortality and morbidity programme) study.
Patients with HF with reduced ejection fraction (HFrEF)
(left ventricular ejection fraction [LVEF] 40%) and
patients with HF with preserved ejection fraction (HFpEF)
LVEF >40%) were included. Less than one-third of the
patients were <60 years of age, and only 2% were regarded
as very young (age <40 years). As expected, idiopathic-
dilated cardiomyopathy was the most common ﬁnding
in the youngest age groups, and this proportion declined
with age. The incidence of HFpEF increased with age,
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Medication use was higher in the younger patients even after
correcting for the proportion of HFpEF, but adherence was
lower. Mortality increased with age, but interestingly, only
in patients >60 years of age. At <60 years of age, 3-year
mortality rates were not signiﬁcantly different, but still
were 12% to 13%. Interestingly, HF hospitalizations were
signiﬁcantly higher in the very young.
A large number of additional important and striking
differences between different age categories were described;
we would like to highlight a few.
First, there was a striking difference in signs and symp-
toms during presentation in younger patients versus older
patients. Younger patients presented with less dyspnea, re-
ﬂected by a lower New York Heart Association functional
class, and they less often had peripheral edema and/or rales.
In contrast, they frequently presented with signs of parox-
ysmal nocturnal dyspnea, increased jugular venous pressure,
and hepatomegaly. These ﬁndings are important for clini-
cians who have to diagnose HF, because mild dyspnea and
absence of peripheral edema and/or rales might easily lead to
a missed diagnosis of HF in younger patients, in particular
because of its low prevalence.
Second, the prevalence of black patients in the youngest
age group was 8 times higher compared with the oldest age
group. This ﬁnding is remarkable, but is supported by other
studies. For example, in a cohort of more than 5,000 sub-
jects, of whom half were black, new-onset HF developed in
27 patients, of whom all but 1 was black (5). These patients
typically had hypertrophic hearts with a dilated ventricle and
impaired systolic function. Although the cause of this higher
prevalence is unclear, a higher burden of hypertension in
combination with a genetic predisposition to cardiomyop-
athy has been postulated (5). Recent surveys from Africa
showed similar results, in which black patients were young,
predominantly had HF from a nonischemic cause, most
commonly had hypertension, and had a high mortality (6,7).
However, a recent survey indicated that lifetime risk for the
development of HF was similar between white and black
Americans. The greater unadjusted risk for HF in blacks and
a similar adjusted lifetime HF risk might be explained by
higher noncardiovascular mortality in blacks, including renal
failure, homicide, and HIV (8).
Third, in patients age <40 years, 100% of deaths had
a cardiovascular cause, whereas in patients in the oldest age
group, 24% of all deaths was noncardiovascular. In general,
once HF has been diagnosed, the majority of these patients
die of a cardiovascular cause, but cardiovascular deaths occur
more often in younger patients. A comparable study has
been performed in young patients (age <40 years) present-
ing with ST-segment elevation myocardial infarction (9). All
deaths except for 1 (suicide) were due to a cardiovascular
origin. This indicates that if cardiac disease strikes the
young, cardiovascular mortality is the leading cause of death.
Fourth, the mortality rate in the very young was similar to
the mortality rate in patients age 50 to 60 years. This is
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mortality signiﬁcantly increases with age. Similar mortality
rates may be related to the fact that the very young could
have had more severe HF compared with patients between
40 and 60 years of age. Inotropes were used more often in
the youngest age group, and their ejection fraction was
lower, although HFpEF was more prevalent in those ages
40 to 60 years. Measurements of natriuretic peptides would
have been helpful to further explore this area. Furthermore,
the very young were signiﬁcantly more often re-hospitalized
due to worsening HF, although this did not translate into
higher mortality rates. Possible factors might be related to
competing risks and lower treatment adherence, but could
also be related to different treatment strategies for the very
young (i.e., inotropes), or simply because the young have
more severe HF. Follow-up time, as the investigators
suggest, might be less likely because mortality rates were
similar for all patient groups <60 years of age.
Next to a wealth of information, the present study byWong
et al. (4) has some limitations. First, this is a substudy of
the CHARM programme, which consisted of 3 large
randomized clinical trials. Patients had to be able to visit the
clinic for their study visits, and therefore, patients were
generally younger than the real-life HF patient population.
Also, the inclusion criteria were enriched by a recent HF
hospitalization. Despite this, the number of patients in the
most interesting group (patients age <40 years) was very
small, as was also admitted by the investigators. Nevertheless,
to our knowledge, this is still the largest reported group of
HF patients age <40 years so far. Second, the investigators
reported a large number of striking differences among the age
groups, but did not attempt to speculate on the potential
clinical consequences of these differences. Also, no data were
provided on the potential differential effects of candesartan
among these age groups. Given the obvious difference in signs
and symptoms and clinical outcome, it might be reasonable to
suggest that diagnosis and treatment of younger HF patients
might differ from the large group of elderly HF patients.
Finally, the CHARM programme was executed in the
late 1990s and early 2000s, with low prescription rates of
beta-blockers, spironolactone, and device therapy, limitingthe extrapolation of their data to the current era to some
extent.
Nevertheless, this study is of great importance, and might
stimulate other groups to study characteristics and clinical
outcome in younger patients with HF, which may lead to
a better diagnosis of and treatment of this small but
important group of patients.
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